Dcfbc | 564482-79-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Dcfbc
• 英文别名: (2S)-2-[[(1R)-1-carboxy-2-[(4-fluorophenyl)methylsulfanyl]ethyl]carbamoylamino]pentanedioic acid
• CAS: 564482-79-7
• 化学式: C₁₆H₁₉FN₂O₇S
• 分子量: 402.4
• InChiKey: IDTMSHGCAZPVLC-RYUDHWBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  178
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY<br/>[FR] INHIBITEURS DE L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) À BASE D'URÉE, POUR IMAGERIE ET TRAITEMENT THÉRAPEUTIQUE
  申请人：FIVE ELEVEN PHARMA INC

  公开号：WO2017116994A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

  本发明涉及符合式I和符合式IV的化合物。这些化合物显示出非常好的结合亲和力，能与PSMA结合位点结合。它们可以用[68Ga]GaCl3标记，产率高，放射化学纯度优秀。本发明还涉及包含药用可接受载体和符合式I或符合式IV的化合物，或其药用可接受盐的药物组合物。
• PSMA imaging agents
  申请人：Wang Eric

  公开号：US10011632B2

  公开（公告）日：2018-07-03

  Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

  本研究公开了用于靶向前列腺特异性膜抗原（PSMA）的化合物和成像剂。还公开了合成化合物和成像剂的方法，以及 PSMA 的成像方法。所公开的成像剂适用于 PET 和 SPECT 成像。
• Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
  申请人：Progenics Pharmaceuticals, Inc.

  公开号：US10340046B2

  公开（公告）日：2019-07-02

  Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.

  本文描述的是一个平台和支持的图形用户界面（GUI）决策工具，供医疗从业人员和/或其患者使用，例如，用于辅助癌症治疗疗程的决策过程和/或跟踪治疗和/或疾病的进展。
• Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10736974B2

  公开（公告）日：2020-08-11

  Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.

  本发明公开了与 PSMA 具有高结合亲和力的氨基甲酸酯和β-氨基酸脲基支架。这些支架可进行放射性标记，用于表达 PSMA 的细胞和肿瘤成像或癌症放射治疗。这些化合物还可以包含荧光染料，用于表达 PSMA 的细胞和肿瘤成像或光动力疗法。
• Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
  申请人：Five Eleven Pharma Inc.

  公开号：US10688200B2

  公开（公告）日：2020-06-23

  The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

  本发明涉及符合式 I 和式 IV 的化合物。这些化合物与 PSMA 结合位点有很好的结合亲和力。它们可以用[68Ga]GaCl3标记，产量高，放射化学纯度极佳。本发明还涉及药物组合物，其中包含药学上可接受的载体和式 I 或式 IV 的化合物或其药学上可接受的盐。